Be the first person to write a business review for ISTA Pharmaceuticals, Inc.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

King Pharmaceuticals was founded in 1993 and is headquartered in Bristol, Tennessee. King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. The company’s branded prescription pharmaceuticals include neuroscience products, such as Skelaxin, Avinza, and Sonata; hospital products, including Thrombin-JMI and Synercid; acute care products that comprise Bicillin and Intal; and legacy products consisting of Altace, Levoxyl, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. Its animal health business focuses on medicated feed additives (MFAs) and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets.King Pharmaceuticals Inc. also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. King Pharmaceuticals also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan and Adenocard. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. Adenocard is a sterile solution of adenosine administered intravenously in emergency situations to convert certain irregular heart rhythms to normal sinus rhythms. It distributes its branded pharmaceutical products through wholesale pharmaceutical distributors and a sales force.

Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania. Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. Lannett company's products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules. In addition, its products consist of pilocarpine HCl, primidone, probenecid, terbutaline sulfate, and unithroid tablets; oxycodone HCl oral solution; rifampin and ursodiol capsules; and phentermine HCl tablets and capsules. Lannett Company markets its products under the brand names of Diamox, Symmetrel, Lioresal, Urecholine, Fiorinal, Cleocin, Danocrine, Bentyl, Lanoxin, Persantine, Adoxa, Periostat, Estratest, Hydrodiuril, Dilaudid, Levoxyl/ Synthroid, Roxanol, PrimaCare ONE, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Actigall, and Fiorinal w/ Codeine #3. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.